HCV elimination in a Swiss opioid agonist therapy programme – a cohort study

HCV elimination in a Swiss opioid agonist therapy programme – a cohort study

BACKGROUND: In opioid agonist therapy (OAT) programmes, chronic hepatitis C is highly prevalent and directly observed therapy guarantees optimal adherence. Since 2017, all patients with chronic hepatitis C in Switzerland can be treated with pangenotypic direct-acting antivirals irrespective of live...

Full description

Bibliographic Details
Main Authors:	Andrea Bregenzer, Cornelia Krismer, Stefanie Wendel, Patrik Roser, Christoph A. Fux
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2022-12-01
Series:	Swiss Medical Weekly
Online Access:	https://smw.ch/index.php/smw/article/view/3257

Similar Items

Hepatitis C virus elimination in Swiss opioid agonist therapy programmes – the SAMMSU cohort
by: Andrea Bregenzer, et al.
Published: (2021-03-01)

Management of hepatitis C in opioid agonist therapy patients of the Swiss canton Aargau within and outside the cohort study
by: Sophie Schürch, et al.
Published: (2020-08-01)

HCV RNA quantification in capillary dried blood spots with the Xpert® HCV Viral Load test for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection
by: Andrea Bregenzer, et al.
Published: (2021-12-01)

Rapid point-of-care HCV RNA quantification in capillary whole blood for diagnosing chronic HCV infection, monitoring treatment and detecting reinfection
by: Andrea Bregenzer, et al.
Published: (2019-10-01)

Hepatitis C prevalence and cascade of care among patients in the decentralised opioid agonist therapy programme of the canton of St Gallen, Switzerland: a cross-sectional study
by: Kerstin Wissel, et al.
Published: (2024-02-01)

Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade
by: Andrea Bregenzer, et al.
Published: (2017-11-01)

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
by: Beat Müllhaupt, et al.
Published: (2018-01-01)

Psychiatrist-led treatment of hepatitis C (HCV) at an opioid agonist treatment (OAT) clinic in Stockholm - enhancing the HCV treatment care cascade
by: M. Kåberg, et al.
Published: (2022-06-01)

Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit
by: Philip Bruggmann, et al.
Published: (2020-09-01)

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.
by: Helen Kovari, et al.
Published: (2015-01-01)

Is HCV elimination possible in prison?
by: J. Crespo, et al.
Published: (2017-01-01)

Is HCV elimination possible in prison?
by: J. Crespo, et al.

The Accessibility of Opioid Agonist Treatment and Its Forced Discontinuation in Swiss Prisons—Attitudes, Perceptions and Experiences of Defense Lawyers in Dealing With Detained Persons Using Opioids
by: Anna Buadze, et al.
Published: (2020-05-01)

Elimination of HCV in Russia: Barriers and Perspective
by: Vasily Isakov, et al.
Published: (2022-04-01)

The knowledge on HCV: from the discovery to the elimination
by: Jun Guan, et al.
Published: (2022-03-01)

Oral Prescription Opioids as a High-Risk Indicator for Hepatitis C Infection: Another Step Toward HCV Elimination
by: Benjamin Hack, et al.
Published: (2021-09-01)

Virological impact of HCV elimination with DAAs in the HIV reservoir in HIV/HCV patients
by: M. Coiras, et al.
Published: (2019-12-01)

Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study
by: Jacques Besson, et al.
Published: (2014-03-01)

P29 Treating hepatitis C virus infection (HCV) with direct acting antivirals (DAAs) through the existing infrastructure of opioid agonist therapy (OAT)
by: J. Keats, et al.
Published: (2017-08-01)

Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013–2017): a prospective cohort study
by: Jørn Henrik Vold, et al.
Published: (2020-07-01)

Elimination of hcv-infection: a history with continuation
by: K. V. Zhdanov, et al.
Published: (2018-12-01)

Evaluating the Impact of Increased Dispensing of Opioid Agonist Therapy Take-Home Doses on Treatment Retention and Opioid-Related Harm among Opioid Agonist Therapy Recipients: A Simulation Study
by: Narjes Shojaati, et al.
Published: (2023-08-01)

Therapeutic Potential of Kappa Opioid Agonists
by: Tyler C. Beck, et al.
Published: (2019-06-01)

Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada
by: David Marsh, et al.
Published: (2024-02-01)

Retention in the Austrian opioid agonist treatment system: a national prospective cohort study
by: Martin Busch, et al.
Published: (2021-02-01)

Interim opioid agonist treatment for opioid addiction: a systematic review
by: Laura Samsó Jofra, et al.
Published: (2022-01-01)

Emergency department contribution to HCV elimination in the Iberian Peninsula
by: Maria Buti, et al.
Published: (2024-01-01)

HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.
by: Jorge Valencia La Rosa, et al.
Published: (2018-01-01)

Cohort profile: the Swiss Cerebral Palsy Registry (Swiss-CP-Reg) cohort study
by: Fabiën N. Belle, et al.
Published: (2022-02-01)

Reply to comment on: Haubitz et al. Outcome of Clostridioides difficile infections treated in a Swiss tertiary care hospital: an observational study
by: Sebastian Haubitz, et al.
Published: (2021-01-01)

O21 HCV reinfection and injecting risk behaviour following elbasvir/grazoprevir treatment in patients on opioid agonist therapy: Co-STAR three year follow-up study
by: G. Dore, et al.
Published: (2017-08-01)

Opioid Agonist Treatment and Risk of Mortality During an Opioid Overdose Public Health Emergency: A Population-Based Retrospective Cohort Study
by: Lindsay A Pearce, et al.
Published: (2020-12-01)

Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project
by: Vincenzo Messina, et al.
Published: (2022-05-01)

Virtual opioid agonist treatment: Alberta’s virtual opioid dependency program and outcomes
by: Nathaniel Day, et al.
Published: (2022-07-01)

HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons
by: Robert Flisiak, et al.
Published: (2022-02-01)

Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy
by: Soroush Moallef, et al.
Published: (2022-12-01)

Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial
by: Irene Pericot-Valverde, et al.
Published: (2020-12-01)

O7 Moving towards HCV elimination in HIV/HCV co- infection in Australia following universal access to interferon-free therapy
by: Marianne Martinello, et al.
Published: (2017-08-01)

Opioid Agonist Therapies and Pregnancy Outcomes for Pregnant People With Opioid Use Disorder: Protocol for a Systematic Review
by: Lindsay A Wilson, et al.
Published: (2023-05-01)

The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study
by: Natasa Gisev, PhD, et al.
Published: (2019-07-01)